KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EBT: 2012-2025

Historic EBT for Sarepta Therapeutics (SRPT) over the last 12 years, with Jun 2025 value amounting to -$383.5 million.

  • Sarepta Therapeutics' EBT fell 2924.76% to -$383.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$164.2 million, marking a year-over-year decrease of 363.88%. This contributed to the annual value of $260.8 million for FY2024, which is 150.14% up from last year.
  • Per Sarepta Therapeutics' latest filing, its EBT stood at -$383.5 million for Q2 2025, which was down 323.31% from $171.7 million recorded in Q4 2024.
  • Over the past 5 years, Sarepta Therapeutics' EBT peaked at $171.7 million during Q4 2024, and registered a low of -$512.7 million during Q1 2023.
  • For the 3-year period, Sarepta Therapeutics' EBT averaged around -$71.4 million, with its median value being $13.6 million (2024).
  • Its EBT has fluctuated over the past 5 years, first spiked by 325.41% in 2024, then slumped by 2,924.76% in 2025.
  • Over the past 5 years, Sarepta Therapeutics' EBT (Quarterly) stood at -$121.9 million in 2021, then grew by 16.89% to -$101.3 million in 2022, then skyrocketed by 139.85% to $40.4 million in 2023, then skyrocketed by 325.41% to $171.7 million in 2024, then tumbled by 2,924.76% to -$383.5 million in 2025.
  • Its last three reported values are -$383.5 million in Q2 2025, $171.7 million for Q4 2024, and $34.0 million during Q3 2024.